Reading CLYM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CLYM free→Reading CLYM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CLYM free→QuarterlyIQ Insights · CLYM
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. As previously disclosed, on March 25, 2025, the Company entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Oppenheimer & Co. Inc., as agent (“Oppenheimer”), pursuant to which the Company could offer and sell shares of Common Stock from time to time through Oppenheimer (the “Oppenheimer ATM Offering”). The Company filed a prospectus supplement with the SEC on March 25, 2025, in connection with the Oppenheimer ATM Offering (the “Oppenheimer Prospectu…
Entry into a Material Definitive Agreement. On June 12, 2026, Climb Bio, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Common Stock”), from time to time through Jefferies. The Company has also filed a prospectus supplement (the “Prospectus Supplement”) relating to the Sales…
Other Events. On June 11, 2026, Climb Bio, Inc. (the “Company”) announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (“ITP”): • The Phase 1b portion of the Phase 1b/2a study (NCT07043946) is evaluating three ascending doses (250 mg, 500 mg and 1000 mg) of intravenous budoprutug, administered in two doses 14 days apart, in adults with primary ITP who have receive…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the 2026 Annual Meeting of Stockholders of Climb Bio, Inc. (the “Company”) held on June 5, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2021 Plan Amendment”) to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) to amend the provision providing for an automatic share pool increase to include prefund…
Other Events. On June 5, 2026, Climb Bio, Inc. (the “Company”) announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody: • A translational pharmacokinetic/pharmacodynamic model derived from pooled non-human primate (“NHP”) data projected healthy human exposure and dose-dependent IgA suppression for CLYM116, suggesting the potential for less-frequent dosing than first generation anti-APRIL approaches. • Literature analysis…
Importance-ranked changes since the prior daily snapshot.
Company momentum rose by 33.3 points (from 6.7 to 40.0).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.